Patrick Urban
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
Journal: The New England journal of medicine
Published: December 09, 2025
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 05, 2021
Application of time-dependent modeling for the exposure-efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients.
Journal: Cancer chemotherapy and pharmacology
Published: October 11, 2018
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Journal: Breast cancer research and treatment
Published: May 14, 2017
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 07, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 06, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: February 03, 2017
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 03, 2016
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
Journal: OncoTargets and therapy
Published: January 22, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026